Bladder cancer treatment developer CG Oncology has filed for an initial public offering with the Securities and Exchange Commission.
The Irvine, California-based biopharmaceutical company is developing a potential treatment for bladder cancer patients who do not respond to Bacillus Calmette-Guerin immunotherapy.
CG Oncology did not say how many shares it plans to offer or give an estimated price range. The company plans to use the proceeds primarily to support operations.
The company has applied to list its shares on the Nasdaq Global Market under the symbol CGON.
Both Morgan Stanley and Goldman Sachs & Co. Cantor and Lifesci Capital are acting underwriters.
